CA2382359A1 - Pharmaceutical preparation containing nanosol - Google Patents

Pharmaceutical preparation containing nanosol Download PDF

Info

Publication number
CA2382359A1
CA2382359A1 CA002382359A CA2382359A CA2382359A1 CA 2382359 A1 CA2382359 A1 CA 2382359A1 CA 002382359 A CA002382359 A CA 002382359A CA 2382359 A CA2382359 A CA 2382359A CA 2382359 A1 CA2382359 A1 CA 2382359A1
Authority
CA
Canada
Prior art keywords
pharmaceutical preparation
preparation containing
nanosol
production
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002382359A
Other languages
French (fr)
Other versions
CA2382359C (en
Inventor
Hans-Rainer Hoffmann
Bodo Asmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2382359A1 publication Critical patent/CA2382359A1/en
Application granted granted Critical
Publication of CA2382359C publication Critical patent/CA2382359C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B01J13/0039—Post treatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to solid pharmaceutical preparations comprising at least one at least partially charged active substance in the form of a nanosol wherein the active substance is bonded to an oppositely charged chitosan derivative, processes for their production, and their use for the production of medicinal products.
CA002382359A 1999-08-27 2000-08-14 Pharmaceutical preparation containing nanosol Expired - Fee Related CA2382359C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19940794.0 1999-08-27
DE19940794A DE19940794A1 (en) 1999-08-27 1999-08-27 Pharmaceutical preparation
PCT/EP2000/007904 WO2001015669A1 (en) 1999-08-27 2000-08-14 Pharmaceutical preparation containing nanosol

Publications (2)

Publication Number Publication Date
CA2382359A1 true CA2382359A1 (en) 2001-03-08
CA2382359C CA2382359C (en) 2008-03-18

Family

ID=7919871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002382359A Expired - Fee Related CA2382359C (en) 1999-08-27 2000-08-14 Pharmaceutical preparation containing nanosol

Country Status (25)

Country Link
EP (1) EP1206253B1 (en)
JP (1) JP2003508423A (en)
KR (1) KR100624499B1 (en)
CN (1) CN1181815C (en)
AR (1) AR025392A1 (en)
AT (1) ATE279180T1 (en)
AU (1) AU779692B2 (en)
BR (1) BR0013563A (en)
CA (1) CA2382359C (en)
CZ (1) CZ301704B6 (en)
DE (2) DE19940794A1 (en)
DK (1) DK1206253T3 (en)
ES (1) ES2231265T3 (en)
HK (1) HK1047037B (en)
HU (1) HU227609B1 (en)
IL (2) IL148220A0 (en)
MX (1) MXPA02002048A (en)
NZ (1) NZ517541A (en)
PL (1) PL203860B1 (en)
PT (1) PT1206253E (en)
RU (1) RU2256440C2 (en)
TR (1) TR200200520T2 (en)
TW (1) TWI267384B (en)
WO (1) WO2001015669A1 (en)
ZA (1) ZA200201135B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100638041B1 (en) * 2003-12-24 2006-10-23 주식회사 삼양사 A nanoparticle composition of a water-soluble drug for oral administration and a preparation method thereof
KR100767336B1 (en) * 2006-04-19 2007-10-18 서평원 Chitin/chitosan based functional organic-inorganic composite material and method for producing the same and use thereof
US9161901B2 (en) 2008-02-21 2015-10-20 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells
UA90013C2 (en) 2008-03-19 2010-03-25 Давид Анатолійович Нога Pharmaceutical composition containing insulin and process for the preparation thereof
PL220269B1 (en) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Composite carrier of powdered medicines, method of production the medicine carrier and equipment for production of particles of composite carrier
DE102009024542A1 (en) * 2009-06-10 2010-12-16 Arivine Pharma Ag Compositions based on chitosan oligosaccharides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474989A (en) * 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
DE4140195C2 (en) * 1991-12-05 1994-10-27 Alfatec Pharma Gmbh Pharmaceutical nanosol and process for its manufacture
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
JPH10513202A (en) * 1996-06-11 1998-12-15 ゾナジェン，インコーポレイテッド Chitosan drug delivery system
ES2114502B1 (en) * 1996-07-29 1999-07-01 Univ Santiago Compostela APPLICATION OF NANOPARTICLES BASED ON HYDROPHILIC POLYMERS AS PHARMACEUTICAL FORMS.
DE19845246A1 (en) * 1997-12-18 1999-06-24 Henkel Kgaa Vitamin E compositions
EP1045700B1 (en) * 1998-01-16 2004-11-10 The Johns Hopkins University Oral delivery of nucleic acid vaccines by particulate complexes

Also Published As

Publication number Publication date
CZ2002653A3 (en) 2002-05-15
KR100624499B1 (en) 2006-09-18
DE50008259D1 (en) 2004-11-18
CN1181815C (en) 2004-12-29
EP1206253B1 (en) 2004-10-13
NZ517541A (en) 2002-08-28
AU779692B2 (en) 2005-02-03
PL203860B1 (en) 2009-11-30
DE19940794A1 (en) 2001-03-01
HK1047037B (en) 2005-03-24
WO2001015669A1 (en) 2001-03-08
ATE279180T1 (en) 2004-10-15
CA2382359C (en) 2008-03-18
PT1206253E (en) 2005-02-28
HU227609B1 (en) 2011-09-28
IL148220A0 (en) 2002-09-12
CN1370065A (en) 2002-09-18
HK1047037A1 (en) 2003-02-07
ES2231265T3 (en) 2005-05-16
HUP0300345A3 (en) 2009-01-28
BR0013563A (en) 2002-07-09
TR200200520T2 (en) 2002-06-21
PL354572A1 (en) 2004-01-26
JP2003508423A (en) 2003-03-04
RU2256440C2 (en) 2005-07-20
HUP0300345A2 (en) 2003-09-29
CZ301704B6 (en) 2010-06-02
AR025392A1 (en) 2002-11-27
DK1206253T3 (en) 2005-01-31
KR20020031416A (en) 2002-05-01
IL148220A (en) 2009-05-04
EP1206253A1 (en) 2002-05-22
TWI267384B (en) 2006-12-01
AU7509400A (en) 2001-03-26
ZA200201135B (en) 2002-08-28
MXPA02002048A (en) 2002-08-20

Similar Documents

Publication Publication Date Title
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2451842A1 (en) Chewable product including active ingredient
CA2154424A1 (en) 1-phenyl-3-dimethylaminopropane compounds having a pharmaceutical effect
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
IE871584L (en) Sustained release capsule.
CA2307018A1 (en) Osmotic medicament releasing system
IE881916L (en) Press-coated dihydropyridine tablets
CA2361981A1 (en) Process for the production of multiple cross-linked hyaluronic acid derivatives
AU3080895A (en) Novel piperazides derived from arylpiperazine, processes for their preparation, their use as medicaments and pharmaceutical compositions comprising them
AU8009998A (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
WO2003011204A3 (en) Drug delivery systems
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
AU7305594A (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation
AU3091489A (en) Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
CA2311450A1 (en) Pharmaceutical aerosol compositions
AU6309698A (en) Drugs containing aminopyridine derivatives as the active ingredient
WO2004017943A3 (en) Non-vesicular cationic lipid formulations
CA2382359A1 (en) Pharmaceutical preparation containing nanosol
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
CA2147759A1 (en) Tilidin dihydrogen orthophosphate, method of preparing it and pharmaceutical preparations containing it
AU4442996A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for the production of pharmaceutical preparations, and pharmaceutical preparations containing them
AU5360890A (en) Substituted azetidinylisothiazolopyridone derivatives, their preparation and their application as medicinal products
ZA969319B (en) Derivatives of imidazole n-benzyldioxole, their preparation process, their use as medicaments, pharmaceutical composition and new use.
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130814